A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Add-On to Standard-of-Care Study of n-Butylphthalide (NBP) Softgel Capsules for Treatment of Mild to Moderate Cortical Acute Ischemic Stroke (AIS) in Adult Subjects

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Add-On to Standard-of-Care Study of n-Butylphthalide (NBP) Softgel Capsules for Treatment of Mild to Moderate Cortical Acute Ischemic Stroke (AIS) in Adult Subjects

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Butylphthalide (Primary) ; Aspirin
  • Indications Stroke
  • Focus Adverse reactions
  • Sponsors CSPC Ouyi Pharmaceutical
  • Most Recent Events

    • 03 Apr 2017 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
    • 03 Apr 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Mar 2020.
    • 03 Apr 2017 Planned initiation date changed from 1 May 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top